Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03056599 · ClinicalTrials.gov registry record · Phase 1
Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO Device in Soft Tissue Sarcoma
A Phase 1 study, sponsored by Presage Biosciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
NCT03056599: Completed Phase 1 study, sponsored by Presage Biosciences.
NCT03056599 is a Phase 1 study that has completed, run by Presage Biosciences. The registered enrollment target is 23 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (62% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03056599, a Phase 1 study, has completed, sponsored by Presage Biosciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
Study Summary
This is a feasibility study in patients with localized or metastatic soft tissue sarcoma undergoing surgery to determine how sarcoma in situ responds to injected microdoses of anti-cancer therapeutics.
Primary Outcome
Analysis will be performed to determine if there is a difference in responses caused by each drug versus the vehicle control
Interventions
- DRUG Multiple drug microinjection
- DEVICE CIVO device
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2016-12-15 |
| Est. Completion | 2021-09-22 |
| Phase | Phase 1 |
What the finished NCT03056599 record still lists
NCT03056599 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 23 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (62% lower).
The record links to 0 conditions, and to 2 interventions - of which Multiple drug microinjection is the first listed.
NCT03056599 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03056599 about?
NCT03056599 is a clinical study titled "Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO Device in Soft Tissue Sarcoma". This is a feasibility study in patients with localized or metastatic soft tissue sarcoma undergoing surgery to determine how sarcoma in situ responds to injected microdoses of anti-cancer therapeutics.
What is the current status of trial NCT03056599?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2016-12-15. Estimated completion is 2021-09-22.
What interventions are being tested in trial NCT03056599?
The interventions under investigation include: Multiple drug microinjection (DRUG), CIVO device (DEVICE).
Who is sponsoring clinical trial NCT03056599?
This trial is sponsored by Presage Biosciences, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03056599's enrollment target sits among peer trials
23 1596th of 2000 higher than 400 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03616041 · 23 participants
Capsule Endoscopy for Severe Hematochezia
- NCT04348747 · 23 participants · Phase 2
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- NCT04587687 · 23 participants · Phase 2
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
- NCT04715022 · 23 participants · Phase 1
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI